JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies

被引:174
作者
Vainchenker, William [1 ,4 ]
Dusa, Alexandra [2 ,3 ]
Constantinescu, Stefan N. [2 ,3 ]
机构
[1] Inst Gustave Roussy PR 1, INSERM U 790, F-94805 Villejuif, France
[2] Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium
[3] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium
[4] Univ Paris 11, F-94805 Villejuif, France
关键词
Janus kinases; JAK2; V617F; Myeloproliferative diseases; Exon; 12; mutations; Acute leukemia; Immunodeficiency;
D O I
10.1016/j.semcdb.2008.07.002
中图分类号
Q2 [细胞生物学];
学科分类号
071009 [细胞生物学]; 090102 [作物遗传育种];
摘要
The four mammalian Janus kinase (JAK) family members, JAK1, JAK2, JAK3 and TYK2, are non-receptor protein tyrosine kinases (PTKs) that are crucial for cytokine receptor signaling in blood formation and immune responses. Mutations and translocations in the JAK genes leading to constitutively active JAK proteins are associated with a variety of hematopoietic malignancies, including the myeloproliferative disorders (JAK2), acute lymphoblastic leukemia (JAK2), acute myeloid leukemia (JAK2, JAK1), acute megakaryoblastic leukemia (JAK2, JAK3) and T-cell precursor acute lymphoblastic leukemia (JAK1). In contrast, loss-of-function mutations of JAK3 and TYK2 lead to immunodeficiency. The role of JAKs as therapeutic targets is starting to expand, as more insights into their structure and activation mechanisms become available. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:385 / 393
页数:9
相关论文
共 121 条
[1]
A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma [J].
Adélaïde, J ;
Pérot, C ;
Gelsi-Boyer, V ;
Pautas, C ;
Murati, A ;
Copie-Bergman, C ;
Imbert, M ;
Chaffanet, M ;
Birnbaum, D ;
Mozziconacci, MJ .
LEUKEMIA, 2006, 20 (03) :536-537
[2]
IDENTIFICATION OF JAK2 AS A GROWTH-HORMONE RECEPTOR-ASSOCIATED TYROSINE KINASE [J].
ARGETSINGER, LS ;
CAMPBELL, GS ;
YANG, XN ;
WITTHUHN, BA ;
SILVENNOINEN, O ;
IHLE, JN ;
CARTERSU, C .
CELL, 1993, 74 (02) :237-244
[3]
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[4]
Bocchia M, 2007, LANCET ONCOL, V8, P864, DOI 10.1016/S1470-2045(07)70295-4
[5]
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog [J].
Boggon, TJ ;
Li, YQ ;
Manley, PW ;
Eck, MJ .
BLOOD, 2005, 106 (03) :996-1002
[6]
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene [J].
Bousquet, M ;
Quelen, C ;
De Mas, V ;
Duchayne, E ;
Roquefeuil, B ;
Delsol, G ;
Laurent, G ;
Dastugue, N ;
Brousset, P .
ONCOGENE, 2005, 24 (48) :7248-7252
[7]
PREVENTION OF T-CELL ANERGY BY SIGNALING THROUGH THE GAMMA(C) CHAIN OF THE IL-2 RECEPTOR [J].
BOUSSIOTIS, VA ;
BARBER, DL ;
NAKARAI, T ;
FREEMAN, GJ ;
GRIBBEN, JG ;
BERNSTEIN, GM ;
DANDREA, AD ;
RITZ, J ;
NADLER, LM .
SCIENCE, 1994, 266 (5187) :1039-1042
[8]
Model for growth hormone receptor activation based on subunit rotation within a receptor dimer [J].
Brown, RJ ;
Adams, JJ ;
Pelekanos, RA ;
Wan, Y ;
McKinstry, WJ ;
Palethorpe, K ;
Seeber, RM ;
Monks, TA ;
Eidne, KA ;
Parker, MW ;
Waters, MJ .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2005, 12 (09) :814-821
[9]
Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients [J].
Butcher, C. M. ;
Hahn, U. ;
To, L. B. ;
Gecz, J. ;
Wilkins, E. J. ;
Scott, H. S. ;
Bardy, P. G. ;
D'Andrea, R. J. .
LEUKEMIA, 2008, 22 (04) :870-873
[10]
Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain [J].
Cacalano, NA ;
Migone, TS ;
Bazan, F ;
Hanson, EP ;
Chen, M ;
Candotti, F ;
O'Shea, JJ ;
Johnston, JA .
EMBO JOURNAL, 1999, 18 (06) :1549-1558